JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

Accueil・Liste d'Actions・Zentalis Pharmaceuticals Inc

Search

Zentalis Pharmaceuticals Inc

Ouvert

4.17 2.96

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.9699999999999998

Max

4.29

Chiffres clés
By Trading Economics
Revenu	-8.5M -35M
Employés	106
EBITDA	-11M -37M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+106.25% upside

Dividendes
By Dow Jones
Prochains Résultats	12 mai 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	138M 301M
Ouverture précédente	1.21
Clôture précédente	4.17

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

1.23 / 1.45 Support & Résistance

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 mai 2026, 22:17 UTC

Résultats

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 mai 2026, 23:47 UTC

Résultats

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 mai 2026, 23:45 UTC

Résultats

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 mai 2026, 23:45 UTC

Résultats

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 mai 2026, 22:44 UTC

Acquisitions, Fusions, Rachats

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 mai 2026, 22:43 UTC

Acquisitions, Fusions, Rachats

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 mai 2026, 22:42 UTC

Acquisitions, Fusions, Rachats

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 mai 2026, 22:42 UTC

Acquisitions, Fusions, Rachats

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 mai 2026, 22:41 UTC

Acquisitions, Fusions, Rachats

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 mai 2026, 22:41 UTC

Acquisitions, Fusions, Rachats

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 mai 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Regis: Shareholders to Own About 51% of Combined Company

4 mai 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Regis: Board Unanimously Endorsed, Supported Deal

4 mai 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Regis: Deal Unanimously Recommended by Vault Board

4 mai 2026, 22:39 UTC

Acquisitions, Fusions, Rachats

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 mai 2026, 22:38 UTC

Acquisitions, Fusions, Rachats

Regis Resources to Acquire All Ordinary Shares in Vault

4 mai 2026, 22:38 UTC

Acquisitions, Fusions, Rachats

Regis Resources, Vault Minerals Agree to Merger of Equals

4 mai 2026, 22:37 UTC

Résultats

Acquisitions, Fusions, Rachats

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 mai 2026, 22:26 UTC

Résultats

Acquisitions, Fusions, Rachats

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 mai 2026, 22:02 UTC

Résultats

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 mai 2026, 21:52 UTC

Résultats

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 mai 2026, 21:50 UTC

Résultats

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 mai 2026, 21:50 UTC

Résultats

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 mai 2026, 21:49 UTC

Résultats

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 mai 2026, 21:44 UTC

Résultats

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 mai 2026, 21:44 UTC

Résultats

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 mai 2026, 21:43 UTC

Résultats

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 mai 2026, 21:41 UTC

Résultats

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 mai 2026, 21:40 UTC

Résultats

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

106.25% hausse

Prévisions sur 12 Mois

Moyen 8.25 USD 106.25%

Haut 10 USD

Bas 4 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

4

Achat

1

Maintien

0

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

1.23 / 1.45Support & Résistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Autres valeurs du secteur

JNJ

Johnson and Johnson

225.55

UNH

UnitedHealth Group Inc

364.08

TMO

Thermo Fisher Scientific Inc

465.22

ISRG

Intuitive Surgical Inc

452.75

ABT

Abbott Laboratories

87.25

Live chat